MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.nephro.2020.03.006

Медицинская библиотека · Nephrologie & therapeutique · 2020

[Carfilzomib-induced haemolytic and uremic syndrome: Favorable outcome with eculizumab].

Casiez Catherine, Pica Gian Matteo, Bally Stéphane

Клинический случайСтатьяПеревод в очереди

Аннотация

Thrombotic microangiopathies are rare diseases characterized by an initial endothelial injury and the formation of thrombi in the microcirculation. Several types of thrombotic microangiopathies can be distinguished: the thrombotic thrombocytopenic purpura; the hemolytic and uremic syndrome, mainly "typical" following a shiga toxin-producing Escherichia coli infection or "atypical" due to a dysregulation of the alternative complement pathway; and "secondary" thrombotic microangiopathies. The use of drug treatments is reported as a frequent cause in this last category and requires stopping the offending drug. We report the case of a patient who developed "secondary" hemolytic and uremic syndrome associated with carfilzomib, a proteasome inhibitor which is used in case of multiple myeloma relapses. Besides stopping the treatment, the patient still showed signs of hemolysis and renal failure with anuria requiring hemodialysis. An eculizumab treatment was therefore initiated. The overall evolution was favorable and an improvement of the renal function promptly allowed the discontinuation of hemodialysis. We discuss the mechanisms that may activate the alternative complement pathway and the potential interest of a transient use of eculizumab in case of carfilzomib-induced hemolytic and uremic syndrome.

Для цитирования: Casiez Catherine, Pica Gian Matteo, Bally Stéphane. [Carfilzomib-induced haemolytic and uremic syndrome: Favorable outcome with eculizumab].. Nephrologie & therapeutique. 2020. DOI: 10.1016/j.nephro.2020.03.006.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.